European Joint Programme on Rare Diseases

European Joint Programme on Rare Diseases
Name	European Joint Programme on Rare Diseases
Abbreviation	EJP RD
Formation	2019
Type	Research programme
Headquarters	Paris
Region served	Europe

Contents

European Joint Programme on Rare Diseases

The European Joint Programme on Rare Diseases is a multinational research initiative linking European Commission, Horizon 2020, Horizon Europe, Commission of the European Communities, European Research Area and European Parliament stakeholders to coordinate research on rare diseases. It aims to align European Union policy, integrate European Molecular Biology Laboratory efforts, harmonize standards used by World Health Organization, support networks such as European Reference Networks, and leverage infrastructures like European Genome-phenome Archive to accelerate diagnosis and therapy development. The programme brings together national institutes, academic consortia, patient organizations including EURORDIS, and funding bodies such as European Investment Bank and Innovative Medicines Initiative to create interoperable resources.

Overview and Mission

The programme's mission aligns with objectives set by Council of the European Union, European Commission Directorate-General for Research and Innovation, European Research Council, European Medicines Agency, and World Health Organization Regional Office for Europe to reduce diagnostic odysseys, improve care pathways, and foster therapeutic innovation. It promotes integration of registries from Orphanet, biobanks like BBMRI-ERIC, genomic datasets from European Nucleotide Archive, and clinical trial platforms such as European Clinical Trials Database to ensure FAIR data use across European Science Foundation, National Institute for Health and Care Research, and national ministries. The programme emphasizes patient-centric research involving groups like Rare Diseases International, Patient-Centered Outcomes Research Institute, and national rare disease alliances.

Origins trace to policy initiatives including the 2008 Council Recommendation on an Action in the Field of Rare Diseases, the International Rare Diseases Research Consortium, and funding frameworks from FP7, Horizon 2020, and Horizon Europe. Early consortia included partners from Institut Pasteur, Karolinska Institutet, King's College London, University of Cambridge, Max Planck Society, and national agencies such as INSERM and Instituto de Salud Carlos III. Milestones mirror events like the launch of European Reference Networks and adoption of the Orphan Drug Regulation, while governance evolved alongside entities such as European Research Area Committee and COST Association networks.

Governance structures involve steering boards with representatives from European Commission Directorate-General for Health and Food Safety, national ministries from France, Germany, Italy, and Spain, research funders like Wellcome Trust, and patient groups including EURORDIS. Funding derives from Horizon 2020 grants, contributions from member states via national research councils such as Agence Nationale de la Recherche, Deutsche Forschungsgemeinschaft, Consiglio Nazionale delle Ricerche, and co-funding by foundations like Gates Foundation and Fondation de France. Oversight engages legal frameworks from European Court of Auditors, ethics review boards including European Network of Research Ethics Committees, and data protection rules under General Data Protection Regulation.

Research spans genomics, biomarkers, natural history studies, and therapeutic development with projects integrating resources from European Genome-phenome Archive, ELIXIR, EATRIS, ECRIN, and ERA-NET. Notable activities include creation of interoperable registries using standards from Human Phenotype Ontology, genotype-phenotype mapping with tools from European Bioinformatics Institute, and clinical trials collaboration drawing on European Clinical Trials Database and networks like European Reference Networks. Workpackages partner with universities such as University of Oxford, Uppsala University, Université Paris Cité, and institutes including Cambridge Biomedical Campus to deliver translational pipelines, leveraging drug discovery expertise from European Medicines Agency interactions and commercialization pathways coordinated with European Investment Fund.

Partnerships encompass EURORDIS, national rare disease alliances, academic centers like Charité – Universitätsmedizin Berlin, research infrastructures such as BBMRI-ERIC and ELIXIR, policy bodies like European Commission, and global initiatives including International Rare Diseases Research Consortium and Global Alliance for Genomics and Health. Industry engagement includes pharmaceutical companies active in orphan drug development represented through European Federation of Pharmaceutical Industries and Associations and biotech clusters such as BioRegion Helsinki. Collaborative projects link to registries like Orphanet, biobanks like UK Biobank, and clinical infrastructures including ECRIN and EATRIS.

The programme advocates adoption of standards from Human Phenotype Ontology, SNOMED CT, ISO, HL7, and interoperability frameworks promoted by ELIXIR and European Health Data Space. Data governance aligns with General Data Protection Regulation and ethics guidance from European Network of Research Ethics Committees while promoting FAIR principles endorsed by Group on Earth Observations–style initiatives and Research Data Alliance. Policies address orphan designation under the Orphan Drug Regulation, regulatory pathways via European Medicines Agency, and reimbursement considerations linked to national health technology assessment agencies like National Institute for Health and Care Excellence.

Outcomes include harmonized registries contributing to diagnostic yield increases documented by partner centers such as Barcelona Children's Hospital, expanded biobank access via BBMRI-ERIC, and catalyzed clinical trials that progressed through European Clinical Trials Database to regulatory interactions with European Medicines Agency. The programme has influenced policy debates in the European Parliament and aided member state strategies coordinated by Council of the European Union. Scientific outputs have appeared in journals associated with Nature Publishing Group, Elsevier, and Springer Nature and collaborations have spurred spin-offs engaging investors such as European Investment Bank and venture funds in the European Innovation Council.

Category:European research programmes